Cerdulatinib is an oral, dual-spleen tyrosine kinase (Syk) and janus kinase (JAK) inhibitor that uniquely inhibits two key cell signaling pathways implicated in certain hematologic malignancies and autoimmune diseases. There is a strong rationale for inhibiting both Syk (B-cell receptor pathway) and JAK (cytokine receptors) in B-cell malignancies where both targets have been shown to promote cancer cell growth and survival. In addition, pre-clinical data suggest an important role for Syk and JAK in peripheral T-cell lymphoma (PTCL) tumor survival.
Cerdulatinib is being developed to treat patients with follicular lymphoma (FL), PTCL, and other hematologic cancers, specifically those who have relapsed or who have not responded to prior therapies.
We are currently enrolling patients in the Phase 2a study evaluating the safety and efficacy of cerdulatinib in patients with relapsed/refractory B-cell malignancies who have failed multiple therapies.
Cerdulatinib is the lead compound in a broader kinase development program consisting of novel, oral small molecules that inhibit Syk and/or JAK, important mediators of immune response in a number of different types of immune cells.
We are currently focused on developing the selective small molecule inhibitors of Syk for the treatment of hematologic cancers and inflammatory diseases. Our lead selective Syk inhibitor candidate is PRT2761, which is being evaluated by Portola and Ora, Inc. as a potential treatment for allergic conjunctivitis.